Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats

B. Stauch Slusher; K. C. Rissolo; K. F. Anzilotti; P. F. Jackson

doi:10.1007/BF02259656

Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats

B. Stauch Slusher, K. C. Rissolo, K. F. Anzilotti, P. F. Jackson

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

It was shown in the present study that three antagonists of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor, including 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466) and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione (YM90K), caused marked reversal of akinesia when administered into the entopeduncular nucleus of rats rendered parkinsonian by bilateral substantia nigra pars compacta lesion. These data suggest that centrally active AMPA antagonists may have therapeutic utility in the treatment of idiopathic Parkinson's disease.

Original language	English (US)
Pages (from-to)	145-149
Number of pages	5
Journal	Journal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume	9
Issue number	2-3
DOIs	https://doi.org/10.1007/BF02259656
State	Published - Jun 1995
Externally published	Yes

Keywords

6-hydroxydopamine
AMPA receptors
GYKI 52466
NBQX
Parkinson's disease
YM90K
dopamine
glutamate
substantia nigra

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology

Access to Document

10.1007/BF02259656

Cite this

@article{f395b186a0fc4b0e8b73c68daa5773dd,

title = "Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats",

abstract = "It was shown in the present study that three antagonists of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor, including 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466) and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione (YM90K), caused marked reversal of akinesia when administered into the entopeduncular nucleus of rats rendered parkinsonian by bilateral substantia nigra pars compacta lesion. These data suggest that centrally active AMPA antagonists may have therapeutic utility in the treatment of idiopathic Parkinson's disease.",

keywords = "6-hydroxydopamine, AMPA receptors, GYKI 52466, NBQX, Parkinson's disease, YM90K, dopamine, glutamate, substantia nigra",

author = "Slusher, {B. Stauch} and Rissolo, {K. C.} and Anzilotti, {K. F.} and Jackson, {P. F.}",

year = "1995",

month = jun,

doi = "10.1007/BF02259656",

language = "English (US)",

volume = "9",

pages = "145--149",

journal = "Acta Neurovegetativa",

issn = "0375-9245",

publisher = "Springer Verlag",

number = "2-3",

}

TY - JOUR

T1 - Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats

AU - Slusher, B. Stauch

AU - Rissolo, K. C.

AU - Anzilotti, K. F.

AU - Jackson, P. F.

PY - 1995/6

Y1 - 1995/6

N2 - It was shown in the present study that three antagonists of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor, including 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466) and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione (YM90K), caused marked reversal of akinesia when administered into the entopeduncular nucleus of rats rendered parkinsonian by bilateral substantia nigra pars compacta lesion. These data suggest that centrally active AMPA antagonists may have therapeutic utility in the treatment of idiopathic Parkinson's disease.

AB - It was shown in the present study that three antagonists of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor, including 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466) and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione (YM90K), caused marked reversal of akinesia when administered into the entopeduncular nucleus of rats rendered parkinsonian by bilateral substantia nigra pars compacta lesion. These data suggest that centrally active AMPA antagonists may have therapeutic utility in the treatment of idiopathic Parkinson's disease.

KW - 6-hydroxydopamine

KW - AMPA receptors

KW - GYKI 52466

KW - NBQX

KW - Parkinson's disease

KW - YM90K

KW - dopamine

KW - glutamate

KW - substantia nigra

UR - http://www.scopus.com/inward/record.url?scp=0029045609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029045609&partnerID=8YFLogxK

U2 - 10.1007/BF02259656

DO - 10.1007/BF02259656

M3 - Article

C2 - 8526999

AN - SCOPUS:0029045609

SN - 0375-9245

VL - 9

SP - 145

EP - 149

JO - Acta Neurovegetativa

JF - Acta Neurovegetativa

IS - 2-3

ER -

Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this